Provided by Tiger Fintech (Singapore) Pte. Ltd.

CASI Pharmaceuticals

1.30
-0.0500-3.72%
Pre-market: 1.23-0.0650-5.02%08:02 EDT
Volume:28.23K
Turnover:36.57K
Market Cap:20.06M
PE:-0.51
High:1.35
Open:1.35
Low:1.27
Close:1.35
Loading ...

CASI Pharmaceuticals Receives Updated Acquisition Proposal for China Operations

TIPRANKS
·
03 Apr

CASI Pharmaceuticals receives proposal to acquire China business for $20M

TIPRANKS
·
03 Apr

CASI Pharmaceuticals - Receipt of Updated Non-Binding Proposal to Acquire Entire China Business of Company

THOMSON REUTERS
·
03 Apr

CASI Pharmaceuticals - Proposed Deal for Purchase Price of $20.0 Mln

THOMSON REUTERS
·
03 Apr

CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company

ACCESS Newswire
·
03 Apr

CASI Pharmaceuticals Q4 Revenue USD 13.4 Million

THOMSON REUTERS
·
31 Mar

CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results

ACCESS Newswire
·
31 Mar

CASI Pharmaceuticals Secures Interim Relief in Juventas Dispute

TIPRANKS
·
10 Feb

This CASI Pharmaceuticals Insider Increased Their Holding By 65% Last Year

Simply Wall St.
·
06 Feb

CASI Pharmaceuticals Faces Asset Freezing Amid Arbitration Dispute

TIPRANKS
·
21 Jan

CASI Pharmaceuticals: Fourth Intermediate People S Court of Beijing Municipality, Granted Juventas Application to Freeze Co's Assets

THOMSON REUTERS
·
21 Jan

CASI Pharmaceuticals Inc: Receives Asset Freezing Order From Court of P.r. China

THOMSON REUTERS
·
21 Jan

CASI Pharmaceuticals: First Patient Dosed in Phase 1/2 Clinical Trial of Cid-103 in Immune Thrombocytopenia

THOMSON REUTERS
·
06 Jan

CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia

ACCESSWIRE
·
06 Jan